XNYSADCT
Market cap192mUSD
Dec 24, Last price
2.03USD
1D
1.53%
1Q
-34.75%
IPO
-93.37%
Name
ADC Therapeutics SA
Chart & Performance
P/E
—
P/S
2.82
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.71%
Rev. gr., 5y
127.56%
Revenues
70m
-66.86%
Net income
-240m
L+54.08%
CFO
-119m
L-13.24%
Earnings
Jun 13, 2025
Profile
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 69,558 -66.86% | 209,908 518.89% | 33,917 | |||||
Cost of revenue | 235,544 | 402,587 | 295,637 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (165,986) | (192,679) | (261,720) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 39,106 | 1,139 | (21,479) | |||||
Tax Rate | ||||||||
NOPAT | (205,092) | (193,818) | (240,241) | |||||
Net income | (240,053) 54.08% | (155,800) -32.27% | (230,026) -6.60% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 773 | 5,909 | 778 | |||||
BB yield | -0.57% | -1.97% | -0.05% | |||||
| Debt | ||||||||
Debt current | 2,934 | 13,571 | 7,604 | |||||
Long-term debt | 134,557 | 111,465 | 102,170 | |||||
Deferred revenue | 23,539 | 23,539 | ||||||
Other long-term liabilities | 312,451 | 214,141 | 260,263 | |||||
Net debt | (142,754) | (232,557) | (398,006) | |||||
| Cash flow | ||||||||
Cash from operating activities | (118,686) | (136,794) | (233,378) | |||||
CAPEX | (3,216) | (2,298) | (6,376) | |||||
Cash from investing activities | (3,216) | (2,508) | (6,673) | |||||
Cash from financing activities | 73,875 | (593) | 267,394 | |||||
FCF | (172,313) | (231,500) | (246,713) | |||||
| Balance | ||||||||
Cash | 278,598 | 326,441 | 466,544 | |||||
Long term investments | 1,647 | 31,152 | 41,236 | |||||
Excess cash | 276,767 | 347,098 | 506,084 | |||||
Stockholders' equity | (1,328,253) | (918,046) | (815,611) | |||||
Invested Capital | 1,618,299 | 1,361,828 | 1,363,498 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 81,712 | 78,153 | 76,748 | |||||
Price | 1.66 -56.77% | 3.84 -80.99% | 20.20 -36.89% | |||||
Market cap | 135,642 -54.80% | 300,107 -80.64% | 1,550,314 -25.96% | |||||
EV | (7,112) | 67,550 | 1,152,308 | |||||
EBITDA | (162,719) | (190,351) | (259,090) | |||||
EV/EBITDA | 0.04 | |||||||
Interest | 46,325 | 36,924 | 18,340 | |||||
Interest/NOPBT | ||||||||